A Pilot Randomized, Placebo Controlled, Double Blind Phase I Trial of the Novel SIRT1 Activator SRT2104 in Elderly Volunteers

Documenti analoghi

• A Randomized, Placebo-Controlled Study of SRT2104, a SIRT1 Activator, in Patients with Moderate to Severe Psoriasis
  di: Krueger, James G., et al.
  Pubblicazione: (2015)
• A phase II, randomized, placebo-controlled, double-blind, multi-dose study of SRT2104, a SIRT1 activator, in subjects with type 2 diabetes
  di: Baksi, Arun, et al.
  Pubblicazione: (2014)
• Cardiovascular Effects of a Novel SIRT1 Activator, SRT2104, in Otherwise Healthy Cigarette Smokers
  di: Venkatasubramanian, Sowmya, et al.
  Pubblicazione: (2013)
• Pharmacokinetics and tolerability of SRT2104, a first-in-class small molecule activator of SIRT1, after single and repeated oral administration in man
  di: Hoffmann, Ethan, et al.
  Pubblicazione: (2013)
• Assessing Colonic Exposure, Safety, and Clinical Activity of SRT2104, a Novel Oral SIRT1 Activator, in Patients with Mild to Moderate Ulcerative Colitis
  di: Sands, Bruce E., et al.
  Pubblicazione: (2015)